Docetaxel plus epirubicin (DE) vs docetaxel plus capecitabine (DC) as 1st line treatment in patients with locally advanced and metastatic breast cancer: a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)

被引：0
|
作者：
Vamvakas, L. [1 ]
Karampeazis, A. [1 ]
Ardavanis, A. [1 ]
Souglakos, I. [1 ]
Kalbakis, K. [1 ]
Vardakis, N. [1 ]
Kouroussis, Ch. [1 ]
Malamos, N. [1 ]
Varthalitis, I. [1 ]
Mavroudis, D. [1 ]
机构：
[1] Univ Gen Hosp Heraklion, Crete, NE USA
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2007年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S49 / S49
页数：1
相关论文
共 50 条
  • [1] A multicenter phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first line treatment in patients with locally advanced and metastatic breast cancer. Preliminary report
    Mavroudis, D
    Boukovinas, I
    Ardavanis, A
    Syrigos, K
    Kouroussis, CH
    Kakolyris, S
    Malamos, N
    Athanasiadis, A
    Varthalitis, I
    Potamianou, A
    Georgoulias, V
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S280 - S280
  • [2] DOCETAXEL PLUS EPIRUBICIN VERSUS DOCETAXEL PLUS CAPECITABINE AS FIRST LINE TREATMENT IN PATIENTS WITH ADVANCED BREAST CANCER. FINAL RESULTS OF A MULTICENTER PHASE III TRIAL
    Mavroudis, D.
    Papakotoulas, P.
    Ardavanis, A.
    Kakolyris, S.
    Kouroussis, C.
    Malamos, N.
    Polyzos, A.
    Christophyllakis, C.
    Kentepozidis, N.
    Geirgoulias, V.
    ANNALS OF ONCOLOGY, 2008, 19 : 63 - 64
  • [3] Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer
    Mavroudis, D.
    Papakotoulas, P.
    Ardavanis, A.
    Syrigos, K.
    Kakolyris, S.
    Ziras, N.
    Kouroussis, C.
    Malamos, N.
    Polyzos, A.
    Christophyllakis, C.
    Kentepozidis, N.
    Georgoulias, V.
    ANNALS OF ONCOLOGY, 2010, 21 (01) : 48 - 54
  • [4] FOLFOXIRI versus FOLFIRI as first line treatment in metastatic colorectal cancer (MCC): A subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)
    Vamvakas, L.
    Androulakis, N.
    Syrigos, K.
    Polyzos, A.
    Ziras, N.
    Athanasiadis, A.
    Kakolyris, S.
    Tsousis, S.
    Kouroussis, Ch.
    Kalykaki, A.
    Samonis, G.
    Mavroudis, D.
    Georgoulias, V.
    Souglakos, J.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 60 : S22 - S23
  • [5] Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients: a prospective randomized phase II study
    Abudureheiyimu, Nilupai
    Wu, Yun
    Li, Qing
    Zhang, Pin
    Ma, Fei
    Yuan, Peng
    Luo, Yang
    Fan, Ying
    Chen, Shanshan
    Cai, Ruigang
    Li, Qiao
    Han, Yiqun
    Xu, Hangcheng
    Wang, Yan
    Wang, Jiayu
    JOURNAL OF THE NATIONAL CANCER CENTER, 2023, 3 (02): : 115 - 120
  • [6] Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG)
    Vamvakas, L.
    Athanasiadis, A.
    Karampeazis, A.
    Kakolyris, S.
    Polyzos, A.
    Kouroussis, Ch.
    Ziras, N.
    Kalbakis, K.
    Georgoulias, V.
    Souglakos, J.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2010, 76 (01) : 61 - 70
  • [7] Survival with docetaxel plus capecitabine comparing with vinorelbine plus capecitabine followed by capecitabine maintenance treatment as first-line therapy in patients with advanced breast cancer: A phase III randomized clinical trial
    Xu, Binghe
    Wang, Jiayu
    Li, Qing
    Zhang, Pin
    Yuan, Peng
    Ma, Fei
    Cai, Ruigang
    Fan, Ying
    Luo, Yang
    Li, Qiao
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Randomized phase III trial comparing TEX (Docetaxel, Epirubicin and Capecitabine) vs. TE (Docetaxel and Epirubicin) In advanced breast cancer patients: findings from the 2nd interim analysis
    Mansutti, Mauro
    Fasola, Gianpiero
    Cavazzini, Giovanna
    Durando, Antonio
    Lo Russo, Vito
    Nardi, Mario
    Boni, Corrado
    Galligioni, Enzo
    Falcone, Alfredo
    Venturini, Marco
    ANNALS OF ONCOLOGY, 2004, 15 : 42 - 42
  • [9] Epirubicin vs epirubicin plus cisplatin vs epirubicin plus lonidamine vs epirubicin plus cisplatin plus lonidamine as first line treatment in advanced breast cancer (BC) patients. A randomized multicenter phase III trial with a factorial design.
    Dogliotti, L
    Berruti, A
    Bitossi, R
    Gorzegno, G
    Bottini, A
    Alquati, P
    De Matteis, A
    Nuzzo, F
    Giardina, B
    Danese, S
    De Lena, M
    Lorusso, V
    Farris, A
    Sarobba, MG
    DeFabiani, E
    Spanu, G
    Bonazzi, G
    Castiglione, F
    Bumma, C
    Moro, G
    Galletto, L
    ANNALS OF ONCOLOGY, 2000, 11 : 41 - 41
  • [10] Oral vinorelbine and gemcitabine (oVG) versus docetaxel and gemcitabine (DG) as first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis for elderly patients of a phase III randomized trial from the Hellenic Oncology Research Group (HORG)
    Vamvakas, L.
    Karampeazis, A.
    Agelaki, S.
    Agelidou, A.
    Kotsakis, A.
    Kakolyris, S.
    Polyzos, A.
    Pallis, A.
    Saloustros, E.
    Georgoulias, V.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 64 : S49 - S49
12345